FDA backs domestic drug development push
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA backed policy proposals in the president’s budget to encourage domestic drug development and manufacturing, focusing on early-stage clinical trials and generics production
- FDA Commissioner Marty Makary stated the agency needs 'giant, big ideas' to counter China’s dominance in early-stage drug development, framing the proposals as strategic responses
- FDA proposed making it easier to run early-stage clinical trials in the U.S., aiming to reduce reliance on overseas testing infrastructure
- FDA suggested giving U.S.-based generic drug manufacturers a competitive advantage, though specifics of the mechanism were not detailed in the content
Why it matters: Drugmakers with U.S. manufacturing capacity could gain a regulatory edge, while reliance on China for early drug development may face new headwinds. The proposals target a structural shift in clinical research and production, though their impact hinges on congressional action that has no defined timeline.
